Platforma

How to Analyze Oxford Nanopore (ONT) Data for Antibody Discovery

A complete workflow for processing, annotating, clonotyping, and analyzing full-length paired antibody sequences from ONT long-read sequencing.

Aug 18

2

July 2026

Structure-based antibody lead selection: how to find the candidates sequence hides

How structure prediction, clustering, and developability analysis turn millions of NGS signals into a smaller, more diverse, more developable lead…

Jul 31

June 2026

Streamlining Peptide Discovery: From NGS to Functional Validation

High-Throughput In Vitro Peptide Discovery

Jun 1

1

March 2026

Beyond Fold Change: Enrichment Quality, Binding Specificity, and Cross-Antigen Analysis

Computationally identify antigen-specific leads without additional wet-lab experiments

Mar 20

2

Beyond Clonal Dominance: Identifying Developable Antibodies from Single-Cell In Vivo Repertoires

An end-to-end workflow for affinity-matured, liability-filtered antibody lead selection

Mar 17

3

February 2026

Platforma vs. Geneious vs. PipeBio: How to choose the best antibody discovery platform in 2026

Key considerations and a detailed comparison of the leading antibody discovery platforms

Feb 4

2

January 2026

Streamlining Antibody Discovery: From NGS to Functional Validation

High-Throughput In Vitro Antibody Discovery

Jan 12

5

The State of Immune Repertoire Analysis: Key TCR/BCR Sequencing Trends Shaping the Next Era

We analyzed metadata from over 3.5 million processed samples from 2024–2025. Here is what the data tells us about the future of immunology.

Jan 5

6

1

October 2025

Case Study: How University of Antwerp differentiated COVID-19 disease severity with T Cell signatures

Discover how MiXCR + QIAGEN streamline TCR sequencing and accelerate breakthroughs in immune research

Oct 10, 2025

September 2025

How to Analyze TCR/BCR Repertoire Diversity and Clonality

Learn what immune repertoire diversity is, key clonality metrics, why downsampling matters, and how to visualize TCR/BCR repertoires for immune…

Sep 20, 2025

1

Case Study: Quotient Tx’s Novel Approach to Drug Development

Leveraging DNA-Based immune profiling with our technology to accelerate target discovery

Sep 8, 2025

1

Launching the Platforma Ambassador Program

Empowering the next generation of scientists to connect, collaborate, and accelerate discovery

Sep 3, 2025